Skip to search formSkip to main contentSkip to account menu

SCH 351125

Known as: SCH-351125, SCH351125 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ancriviroc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
What is the future of CCR5 antagonists in rheumatoid arthritis?
Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5… 
2007
2007
Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
Highly Cited
2005
Highly Cited
2005
The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor
4-{[4-({(3R)-1-Butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenyl]oxy}benzoic acid… 
2003
2003
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
The small-molecule CCR5 antagonist SCH-C (SCH 351125) was tested for its ability to inhibit HIV-1 replication in peripheral blood… 
2003
2003
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
Review
2002
Review
2002
Sch-351125 and Sch-350634. Schering-Plough.
Schering-Plough is developing Sch-351125 (Sch-C), the lead in a series of CCR5 inhibitors, for the potential treatment of HIV… 
Highly Cited
2002
Highly Cited
2002
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4… 
Review
2002
Review
2002
Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents
HIV entry within the cell involves the presence of at least two chemokine co-receptors, the CCR5 and CXCR4 receptors. Viral entry… 
Highly Cited
2001
Highly Cited
2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
We describe here the identification and properties of SCH-C (SCH 351125), a small molecule inhibitor of HIV-1 entry via the CCR5… 
Highly Cited
2001
Highly Cited
2001
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for…
Structure-activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)